Replies to post #10443 on SCIENCE SPIN-OFFS

[BottomBounce]

$IBIO Using its plant-based FastPharming® System, iBio has successfully expressed N protein antigens and has initiated both intramuscular and intranasal preclinical studies to identify favorable antigen-adjuvant combinations. Results are expected in early Q1 FY2022. iBio recently filed four provisional patent applications with the U.S. Patent and Trademark Office in support of the IBIO-202 program.

[BottomBounce]

$CVSI CV Sciences, Inc. operates as a life science company. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The Consumer Products segment develops, manufactures, and markets hemp-based cannabidiol (CBD) products under the name of PlusCBD in a range of market sectors, including nutraceutical, beauty care, and specialty foods. It serves internet sales, direct-to-consumer health and wellness stores, collectives, cooperatives, master distributors, specialty retailers, and convenience stores, as well as food, drug, and mass merchandise retailers. The Specialty Pharmaceutical segment focuses on developing and commercializing cannabinoids to treat medical indications. Its products product candidates are based on proprietary formulations, processes, and technology. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California. https://finance.yahoo.com/quote/CVSI?p=CVSI&.tsrc=fin-srch

[BottomBounce]

$IBIO Biotech LOW FLOAT Stock